THERAPY DOSSIER · th-220c9f292ff8

Primary human amnion epithelial cells (hAECs)

Biologic · Cell therapy (human amnion epithelial cells); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Cell therapy (human amnion epithelial cells); not a ChEMBL entity
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03107975 ↗PHASE1unknown

Intrathecal Transplant of Human Amniotic Epithelial Cells in Spastic Cerebral Palsy

Spastic Cerebral Palsy

Enrolment: 10 · Results not recorded

NCT04728906 ↗NAunknown

Epithelial Stem Cells and Cardiomyocytes in Amnion Bilayer to Regenerate Myocardial Infarction

Myocardial Infarction

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22507554 ↗2012Mixed findings

Human amnion epithelial cells do not abrogate pulmonary fibrosis in mice with impaired macrophage function.

MouseChemical/toxinSurfactant protein C deficient (Sftpc-/-) and wild-type (Sftpc+/+)24 hours after bleomycin exposure

Model: Bleomycin-induced lung injury and pulmonary fibrosis

In wild-type mice hAECs decreased pro-inflammatory gene expression, macrophage and neutrophil infiltration, fibrosis, collagen and alpha-smooth muscle actin and improved lung function. In Sftpc-/- mice with impaired macrophage function hAECs produced no reduction in inflammation, fibrosis or functi…

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…